For a few decades, the worlds of biotech and digital technology have been on separate paths. Franck Lescure, Partner at the French VC firm Elaia Partners, explains how the two fields are now colliding and how investors need to catch up.
At first glance, digital technology and biotech are widely different fields, each with their own standards for investments and founding startups. According to Franck Lescure at Elaia, though, the difference in technology doesn’t mean that the two can’t mix.
“There is no incompatibility between digital and life sciences, and more and more you see very interesting projects, especially in the deep tech area,” Lescure told me.
Lescure began his career in the life sciences as a scientist at the French biotech Genset, and afterward as a product manager at a healthcare subsidiary of the gas supplier Air Liquide. Following this, he became an investor at Crédit Lyonnais Private Equity and later at Auriga Partners. When he joined Elaia in 2018, he was ready to offer his skills to a more digital tech-focused investor.
“I was experiencing the emergence of bio-digital projects for which I was quite unarmed, or without sufficient experience to deal with the digital component of the project,” he noted.
“Elaia was talking to me sometimes about projects where they were very comfortable on the digital side of some project,
The post Investors Must Be Ready for the Digitization of Biotech appeared first on Labiotech.eu.